Osteoarthritis pain in dogs: does adding amantadine to an NSAID improve activity when the NSAID alone is not enough? — POSSIBLE

In dogs with osteoarthritis pain refractory to NSAIDs, does adding amantadine vs placebo improve activity and pain scores?

Shelf #509 · gate-verified and displayed under the developer's blinded-trial rule

POSSIBLE: In dogs whose osteoarthritis pain was refractory to NSAIDs, adding amantadine to meloxicam improved owner-assessed activity in the single randomised trial. In Lascelles 2008 (31 client-owned dogs with pelvic limb lameness despite NSAID administration; randomised, blinded, placebo-controlled, parallel groups), all dogs received meloxicam from day 7, and from day 21 received amantadine (3–5 mg/kg orally once daily) or placebo for 21 days: for client-specific outcome measure (CSOM) activity there was a significant time-by-treatment effect (P = .009), and on the planned post hoc test the amantadine group was significantly more active than the placebo group on day 42 (P = .030). Design class (a): randomisation and blinding are both established by the carded record — Lascelles 2008 states 'randomized, blinded, and placebo controlled' in its own wording, with publication type Randomized Controlled Trial and MeSH Double-Blind Method. The honest limits: this is ONE trial of 31 dogs; the record gives no group mean activity scores, so the size of the improvement cannot be stated, only its direction and significance; the significant between-group difference rests on a post hoc day-42 comparison after 21 days of add-on treatment; and the primary outcome is owner-assessed activity, not an objective gait measure. A single small trial cannot carry PROBABLE, so the stamp is POSSIBLE. Drafted Nov 10, 2026 (VetMed build, topic #509); all figures from the abstract fetched and verified at drafting.

Lascelles 2008: dogs with NSAID-refractory osteoarthritis pain given amantadine added to meloxicam were significantly more active than placebo dogs at day 42 (time-by-treatment P = .009; day 42 P = .030)

Randomized, blinded, placebo-controlled trial with parallel groups (record's own wording: 'randomized, blinded, and placebo controlled'; publication type: Randomized Controlled Trial; MeSH includes Double-Blind Method)

Who: Dogs: 31 client-owned dogs with pelvic limb lameness despite the administration of an NSAID (osteoarthritis pain refractory to NSAIDs), in a multicentre clinical setting. On day 0, analgesic medications were discontinued; on day 7, all dogs received meloxicam for 5 weeks; on day 21, all dogs received amantadine (3–5 mg/kg once daily per os) or placebo for 21 days, in addition to meloxicam. Assessments were performed before the study and on days 7, 21 and 42; the primary outcome was blinded owner assessment of activity using client-specific outcome measures (CSOM).

Result: For CSOM activity, there was a significant time by treatment effect (P = .009). On the basis of the planned post hoc t-tests of postrandomization means, there was a significant difference between treatment groups on day 42 (P = .030), with the amantadine group being more active. The record's conclusion: in dogs with osteoarthritic pain refractory to an NSAID, physical activity is improved by the addition of amantadine. The record gives no group mean CSOM scores, so the magnitude of the improvement cannot be stated from this record.

Watch out: One trial, 31 dogs, and the headline between-group difference is a post hoc day-42 test within a significant overall time-by-treatment effect — supportive, not decisive. The primary outcome is owner-reported activity (CSOM), assessed blind; no objective gait or force-plate result is reported in this record, and the abstract reports no significant result for pain scores as distinct from activity. The add-on period was only 21 days, on a meloxicam background after a washout-and-restabilisation run-in, so the result applies to that protocol, not to amantadine started alongside any NSAID at any time.

Lascelles BD, Gaynor JS, Smith ES, Roe SC, Marcellin-Little DJ, Davidson G, Boland E, Carr J. Amantadine in a multimodal analgesic regimen for alleviation of refractory osteoarthritis pain in dogs. J Vet Intern Med. 2008;22(1):53-9. PMID: 18289289. Registry ID: none in the record. MeSH: Amantadine/administration & dosage, therapeutic use* · Analgesics, Non-Narcotic/therapeutic use* · Animals · Dog Diseases/drug therapy*, etiology · Dogs · Double-Blind Method · Drug Administration Schedule/veterinary · Female · Male · Osteoarthritis/complications, drug therapy, veterinary* · Pain/drug therapy, etiology, veterinary*

Synthesis: one small blinded placebo-controlled trial shows amantadine added to meloxicam improves activity in NSAID-refractory canine osteoarthritis — POSSIBLE

Synthesis

Who: Synthesis of the card above: Lascelles 2008, the only randomised trial of amantadine for canine osteoarthritis pain found on PubMed search this session (31 client-owned dogs with pelvic limb lameness despite NSAID administration; amantadine 3–5 mg/kg once daily or placebo added to meloxicam for 21 days).

Result: (1) The trial was randomised, blinded and placebo-controlled, in exactly the mined population — dogs whose osteoarthritis pain had not responded to an NSAID alone. (2) The primary outcome, blinded owner-assessed activity (CSOM), showed a significant time-by-treatment effect (P = .009) favouring amantadine. (3) The between-group difference was significant at the end of the add-on period, day 42 (P = .030). One well-designed but small trial with a significant primary outcome and no replication supports POSSIBLE, not more.

Watch out: No second randomised trial of amantadine in canine osteoarthritis exists in the records found — the rest of the amantadine-in-dogs literature located is pharmacokinetic studies, reviews and a single case report in neuropathic pain, none of which can carry this claim and none of which is carded. The evidence does not address amantadine as sole therapy, amantadine with NSAIDs other than meloxicam, treatment beyond 21 days, or objective gait outcomes.

Synthesis of Lascelles BD et al. PMID: 18289289. Registry ID as on the individual card.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.